Geron (GERN) Profit After Tax (2010 - 2026)
Geron (GERN) posted Profit After Tax of -$3.6 million for Q1 2026, up 87.38% sequentially from -$28.9 million in Q4 2025, and up 81.64% YoY from -$2.0 million in Q1 2025.
Geron (GERN) Profit After Tax (2010 - 2026) Analysis & Trends
Geron has reported Profit After Tax for 17 years, with the latest figure at -$3.6 million in Q1 2026.
- Quarterly Profit After Tax rose 81.64% year-over-year to -$3.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$67.3 million (up 51.58% YoY) and the FY2025 annual result came in at -$83.5 million, up 52.17% from the prior year.
- Profit After Tax rose to -$3.6 million in Q1 2026 per GERN's latest filing, from -$28.9 million in the prior quarter.
- Over five years, Profit After Tax peaked at -$3.6 million in Q1 2026 and troughed at -$67.4 million in Q2 2024.
- A 5-year average of -$34.6 million and a median of -$30.1 million in 2022 frame the typical range for Profit After Tax.
- The sharpest annual moves came in 2023 and 2026: Profit After Tax plunged 75.08% in 2023, then jumped 81.64% in 2026.
- Over 5 years, Profit After Tax stood at -$42.6 million in 2022, then retreated by 21.9% to -$52.0 million in 2023, then surged by 51.22% to -$25.4 million in 2024, then decreased by 13.85% to -$28.9 million in 2025, then soared by 87.38% to -$3.6 million in 2026.
- According to Business Quant data, Profit After Tax over the past three periods registered -$3.6 million, -$28.9 million, and -$18.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -16.62 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Geron | 1.02 Mn | -299.83 Mn | - | -16.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -16.68 Mn |
| Mar 31, 2026 | -3.64 Mn |
| Dec 31, 2025 | -28.86 Mn |
| Sep 30, 2025 | -18.43 Mn |
| Jun 30, 2025 | -16.38 Mn |
| Mar 31, 2025 | -19.84 Mn |
| Dec 31, 2024 | -25.35 Mn |
| Sep 30, 2024 | -26.45 Mn |
| Jun 30, 2024 | -67.38 Mn |
| Mar 31, 2024 | -55.39 Mn |
| Dec 31, 2023 | -51.97 Mn |
| Sep 30, 2023 | -44.81 Mn |
| Jun 30, 2023 | -49.23 Mn |
| Mar 31, 2023 | -38.12 Mn |
| Dec 31, 2022 | -42.64 Mn |
| Sep 30, 2022 | -41.05 Mn |
| Jun 30, 2022 | -28.12 Mn |
| Mar 31, 2022 | -30.10 Mn |
| Dec 31, 2021 | -32.02 Mn |
| Sep 30, 2021 | -26.70 Mn |